Q3 EPS Estimates for Ikena Oncology Raised by William Blair

Key Points

• William Blair analysts raised their Q3 2025 EPS estimate for Ikena Oncology to ($1.00), significantly up from the previous estimate of ($1.68).
• Ikena Oncology's shares fell by 3.5%, opening at $17.28, with a market cap of $69.47 million.
• Significant insider transactions included Director Otello Stampacchia purchasing 267,556 shares at nearly $29.90 each, increasing his position by over 142%.

Ikena Oncology, Inc. (NASDAQ:IMA - Free Report) - William Blair raised their Q3 2025 earnings per share estimates for shares of Ikena Oncology in a research note issued to investors on Wednesday, July 30th. William Blair analyst M. Phipps now expects that the company will post earnings of ($1.00) per share for the quarter, up from their previous forecast of ($1.68). The consensus estimate for Ikena Oncology's current full-year earnings is ($0.91) per share. William Blair also issued estimates for Ikena Oncology's Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($0.99) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.32) EPS, FY2027 earnings at ($6.12) EPS and FY2028 earnings at ($7.24) EPS.

Separately, Wedbush cut their price target on Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th.

Ikena Oncology Price Performance

Shares of NASDAQ IMA traded down $0.57 during mid-day trading on Monday, reaching $15.18. 8,125 shares of the company's stock were exchanged, compared to its average volume of 14,254. Ikena Oncology has a 52 week low of $11.65 and a 52 week high of $23.28. The firm has a market capitalization of $61.02 million, a price-to-earnings ratio of -1.98 and a beta of 0.51. The firm has a 50-day moving average price of $16.12 and a two-hundred day moving average price of $15.73.

Ikena Oncology (NASDAQ:IMA - Get Free Report) last posted its earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08.

Insiders Place Their Bets

In related news, Director David P. Bonita bought 83,611 shares of the business's stock in a transaction dated Friday, July 25th. The shares were bought at an average cost of $29.90 per share, with a total value of $2,499,968.90. Following the completion of the transaction, the director directly owned 287,885 shares of the company's stock, valued at approximately $8,607,761.50. This trade represents a 40.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Otello Stampacchia bought 267,556 shares of the firm's stock in a transaction on Friday, July 25th. The stock was acquired at an average cost of $29.90 per share, with a total value of $7,999,924.40. Following the completion of the transaction, the director directly owned 454,982 shares of the company's stock, valued at approximately $13,603,961.80. This represents a 142.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 5.94% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BML Capital Management LLC raised its stake in Ikena Oncology by 3.5% in the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company's stock valued at $4,750,000 after buying an additional 124,937 shares during the period. Gilead Sciences Inc. bought a new stake in shares of Ikena Oncology during the 4th quarter worth $3,294,000. Geode Capital Management LLC boosted its position in Ikena Oncology by 21.0% during the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after buying an additional 56,936 shares during the period. Aldebaran Capital LLC bought a new position in Ikena Oncology during the 1st quarter valued at approximately $317,000. Finally, JPMorgan Chase & Co. raised its position in shares of Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock worth $255,000 after purchasing an additional 154,892 shares during the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

About Ikena Oncology

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.